MA30564B1 - Procédé de fabrication des sels de n-hydroxy-3-[4-[[[2-(2-méthyl-1h-indol-3-yl)éthyl]amino]méthyl]phényl]-2e-2-propénamide. - Google Patents

Procédé de fabrication des sels de n-hydroxy-3-[4-[[[2-(2-méthyl-1h-indol-3-yl)éthyl]amino]méthyl]phényl]-2e-2-propénamide.

Info

Publication number
MA30564B1
MA30564B1 MA31474A MA31474A MA30564B1 MA 30564 B1 MA30564 B1 MA 30564B1 MA 31474 A MA31474 A MA 31474A MA 31474 A MA31474 A MA 31474A MA 30564 B1 MA30564 B1 MA 30564B1
Authority
MA
Morocco
Prior art keywords
methyl
propenamide
indol
hydroxy
phenyl
Prior art date
Application number
MA31474A
Other languages
English (en)
Inventor
Joginder S Bajwa
David John Parker
Joel Slade
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30564(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30564B1 publication Critical patent/MA30564B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LES SELS DE N-HYDROXY-3-[4-[[[2-(2-MÉTHYL-1H-INDOL-3-YL) ÉTHYL]AMINO]MÉTHYL]PHÉNYL]-2E-2-PROPÉNAMIDE FAISANT L'OBJET DE LA PRÉSENTE INVENTION SONT PRÉPARÉS AU MOYEN DE DIVERS PROCÉDÉS.
MA31474A 2006-06-12 2008-12-12 Procédé de fabrication des sels de n-hydroxy-3-[4-[[[2-(2-méthyl-1h-indol-3-yl)éthyl]amino]méthyl]phényl]-2e-2-propénamide. MA30564B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80452906P 2006-06-12 2006-06-12
US85325906P 2006-10-20 2006-10-20

Publications (1)

Publication Number Publication Date
MA30564B1 true MA30564B1 (fr) 2009-07-01

Family

ID=38832680

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31474A MA30564B1 (fr) 2006-06-12 2008-12-12 Procédé de fabrication des sels de n-hydroxy-3-[4-[[[2-(2-méthyl-1h-indol-3-yl)éthyl]amino]méthyl]phényl]-2e-2-propénamide.

Country Status (23)

Country Link
US (1) US7989639B2 (fr)
EP (1) EP2032532B8 (fr)
JP (1) JP2009540007A (fr)
KR (1) KR20090026282A (fr)
AR (1) AR061295A1 (fr)
AU (1) AU2007257882B2 (fr)
BR (1) BRPI0713653A2 (fr)
CA (1) CA2654230C (fr)
CL (1) CL2007001690A1 (fr)
EC (1) ECSP088957A (fr)
GT (1) GT200800281A (fr)
IL (1) IL195344A (fr)
JO (1) JO3099B1 (fr)
MA (1) MA30564B1 (fr)
MX (1) MX2008015899A (fr)
MY (1) MY147013A (fr)
NO (1) NO20090136L (fr)
NZ (1) NZ572744A (fr)
PE (1) PE20080365A1 (fr)
RU (1) RU2008151724A (fr)
TN (1) TNSN08508A1 (fr)
TW (1) TWI385142B (fr)
WO (1) WO2007146717A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMP200900002B (it) * 2006-06-12 2010-01-19 Novartis Ag Sali di n-idrossi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]ammino]metil]fenil]-2e-2-propenammide
IN2015DN00910A (fr) * 2006-06-12 2015-07-10 Novartis Ag
AU2008204928B2 (en) * 2007-01-10 2011-03-31 Novartis Ag Formulations of deacetylase inhibitors
JP5485138B2 (ja) * 2008-03-28 2014-05-07 浜理薬品工業株式会社 エチニルチミジン化合物の精製方法
CA2929309C (fr) * 2013-12-02 2018-07-03 Suven Life Sciences Limited Procede pour la production a grande echelle de 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
WO2017221163A1 (fr) * 2016-06-21 2017-12-28 Alembic Pharmaceuticals Limited Nouveaux sels et formes polymorphes de panobinostat
WO2018092151A1 (fr) * 2016-11-21 2018-05-24 Msn Laboratories Private Limited, R&D Center Procédé de préparation de l'acide 2- (e)-n-hydroxy-3-[4- [[ [2- (2-méthyl -1 h-indol-3-yl) éthyl] amino] méthyl] phényl]-2-propénamide 2-hydroxypropanoïque (1 : 1) et ses polymorphes
WO2018163114A1 (fr) * 2017-03-10 2018-09-13 Shilpa Medicare Limited Panobinostat amorphe et son sel de lactate
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US12084450B2 (en) * 2022-06-27 2024-09-10 Abion Inc. Mesylate salts of triazolopyrazine derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH342565A (de) 1954-04-14 1959-11-30 Thomae Gmbh Dr K Verfahren zur Herstellung von basischen Äthern endocyclisch substituierter Carbinole oder ihren nicht quaternären Salzen
GB891413A (en) 1958-10-06 1962-03-14 Smith Kline French Lab Tris-(dialkylaminoalkyl) phosphates and a method for their preparation
GB8600397D0 (en) 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60215028T2 (de) * 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
NZ544689A (en) 2001-11-06 2007-08-31 Novartis Ag Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
US20040224952A1 (en) * 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
WO2005105740A2 (fr) 2004-04-26 2005-11-10 Teva Pharmaceutical Industries Ltd. Préparation de tégasérode et de maléate de tégasérode
TW200613275A (en) 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts

Also Published As

Publication number Publication date
US7989639B2 (en) 2011-08-02
HK1126495A1 (en) 2009-09-04
BRPI0713653A2 (pt) 2012-10-23
CA2654230C (fr) 2012-09-11
AR061295A1 (es) 2008-08-20
TNSN08508A1 (en) 2010-04-14
NO20090136L (no) 2009-03-06
KR20090026282A (ko) 2009-03-12
MX2008015899A (es) 2009-04-01
TWI385142B (zh) 2013-02-11
EP2032532B8 (fr) 2015-07-01
IL195344A (en) 2014-11-30
NZ572744A (en) 2011-05-27
CL2007001690A1 (es) 2008-05-16
MY147013A (en) 2012-10-15
RU2008151724A (ru) 2010-07-20
PE20080365A1 (es) 2008-05-07
GT200800281A (es) 2009-03-18
WO2007146717A3 (fr) 2008-03-27
JP2009540007A (ja) 2009-11-19
JO3099B1 (ar) 2017-03-15
AU2007257882B2 (en) 2011-09-08
WO2007146717A2 (fr) 2007-12-21
US20090187029A1 (en) 2009-07-23
TW200808692A (en) 2008-02-16
IL195344A0 (en) 2009-08-03
ECSP088957A (es) 2009-01-30
EP2032532B1 (fr) 2015-04-22
CA2654230A1 (fr) 2007-12-21
AU2007257882A1 (en) 2007-12-21
EP2032532A2 (fr) 2009-03-11

Similar Documents

Publication Publication Date Title
MA30511B1 (fr) Polymorphes de n-hydroxy -3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2- propenamide
AR061298A1 (es) Sales de n-hidroxi -3- [4- [ [ [2- (2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2- propenamida.composciones farmaceuticas.
JO3099B1 (ar) طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد
CY1113547T1 (el) Διαδικασια συνθεσης ενωσεων χρησιμων στην αντιμετωπιση της ηπατιτιδας c
WO2008081582A1 (fr) Boisson conditionnée
EA201070116A1 (ru) Новые кристаллы и способ получения 5-({[2-амино-3-(4-карбамоил-2,6-диметилфенил)пропионил]-[1-(4-фенил-1н-имидазол-2-ил)этил]амино}метил)-2-метоксибензоевой кислоты
MA33378B1 (fr) Nouveaux sels de fumarate d'un antagoniste des récepteurs h3 de l'histamine
ZA200809383B (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl] amino]methyl]phenyl]-2E-2propenamide
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
IL233836A0 (en) Method for preparing n-hydroxy-3-[4-[[[2-(2-methyl-h1-indol-3-yl)ethyl]amino]methyl]phenyl]-e2-2-propanamide
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
TW200605798A (en) Non-essential amino acids containing pharmaceutical composition and uses thereof
DOP2008000068A (es) Polimorfos de n-hidroxi-3[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
CY1114470T1 (el) Διαδικασια για την παρασκευη ν- υδροξυ-3-ý4-ýýý2-(2-μεθυλο-1η-ινδολ-3- υλ) αιθυλο ¨αμινο¨ μεθυλο ¨φαινυλο¨-2ε-2- προπεναμιδιου και τα υλικα εναρξης αυτων